Paraneoplastic Papuloerythroderma of Ofuji Masquerading as Worsening Psoriasis Authors: Megan Hauptman, Nikhil Mehta, Frank Wang, Lori Lowe, Mio Nakamura Published: 2026 ABSTRACT AbstractParaneoplastic papuloerythroderma of Ofuji (PEO) is a rare cause of exfoliative erythroderma characterized by intensely pruritic, generalized erythema and scale with relative sparing of the skin folds (deck-chair sign) and is frequently associated with underlying malignancy, most commonly cutaneous T-cell lymphoma (CTCL). We present a unique case of paraneoplastic PEO in a patient with a history of plaque psoriasis whose rash suddenly began to worsen despite treatments for psoriasis. He developed diffuse brightly erythematous plaques with sparing fo the skin folds and hyperkeratotic, fissured plaques on the palms and soles. This ultimately led to hospitalization for erythroderma. Upon further work up, he was found to have squamous cell carcinoma of the lung by computed tomography. This case underscores that abrupt erythrodermic worsening in a patient with known psoriasis should prompt evaluation for an underlying paraneoplastic process rather than being attributed to psoriasis progression alone. Introduction Paraneoplastic papuloerythroderma Ofuji (PEO) is a rare exfoliative erythroderma characterized by severe pruritus with diffuse erythema and scaling with relative sparing of the skin folds.1 It is often associated with an underlying malignancy. Recognition can be particularly challenging in patients with pre-existing inflammatory dermatoses, as new paraneoplastic erythroderma may be misattributed to progression or treatment failure of the underlying condition. We describe a unique case of paraneoplastic PEO in a patient with longstanding plaque psoriasis whose rash abruptly worsened despite ongoing psoriasis-directed therapy. Case Report A 66-year-old man with a 5-year history of plaque psoriasis and heavy tobacco (83 pack-years) and alcohol use presented with a 12-week history of worsening psoriasis and pruritus. He was enrolled in a clinical trial of an investigational oral interleukin-23 receptor inhibitor. Initially, his psoriasis improved, but around week 16 of the study it began to worsen. A punch biopsy showed a psoriasiform and spongiotic dermatitis with small lymphoid cells and scattered eosinophils. Immunohistochemistry revealed predominately CD3+ T-lymphocytes with a CD4:CD8 ratio of 2:1. These findings were interpreted as partially treated psoriasis with a possible superimposed drug eruption. The study drug was discontinued, and the patient was treated with a prednisone taper and topical steroids, followed by bimekizumab. However, his skin disease continued to worsen over 5 months, progressing to diffuse, brightly erythematous and violaceous plaques with fine scale; tender, hyperkeratotic, fissured plaques on the palms and soles; and sparing of skin folds on the trunk (Figure 1a–c). He denied fever, cough, or unintentional weight loss, and did not have lymphadenopathy on examination. He was ultimately hospitalized for erythroderma (80% BSA). Labs revealed mild eosinophilia (11.7%), mild lymphocytopenia (0.9 K/uL) and an elevated lactate dehydrogenase (LDH) of 273 U/L. A second biopsy from the forearm showed a spongiotic psoriasiform dermatitis with scattered eosinophils and increased lymphocytes (Figure 2). Figure 1Paraneoplastic papuloerythroderma of Ofuji. Clinical photographs showing erythroderma with erythematous, scaly plaques on the (a) palms and (b) posterior trunk, and on the (c) anterior trunk with relative sparing of the abdominal skin folds (deck-chair sign).The image A shows palms with erythroderma, displaying erythematous and scaly plaques. The image B shows the posterior trunk with diffuse erythematous plaques. The image C shows the anterior trunk with similar plaques, with relative sparing of the abdominal skin folds, known as the deck-chair sign. These images illustrate the condition known as paraneoplastic papuloerythroderma of Ofuji.Clinical images showing erythroderma with erythematous plaques on palms, posterior trunk and anterior trunk. Figure 2Paraneoplastic papuloerythroderma of Ofuji. Skin biopsy showing psoriasiform epidermal hyperplasia with focal lymphocytic spongiosis and superficial perivascular lymphocytic inflammation with scattered eosinophils (H&E, ×200).The image shows a skin biopsy with psoriasiform epidermal hyperplasia. The epidermis displays thickening with elongated rete ridges. There is focal lymphocytic spongiosis, indicating the presence of lymphocytes within the epidermis. Below the epidermis, the dermis shows superficial perivascular lymphocytic inflammation, characterized by clusters of lymphocytes around blood vessels. Scattered eosinophils are also visible within the inflammatory infiltrate. This histological pattern is consistent with the description of paraneoplastic papuloerythroderma of Ofuji.Skin biopsy showing psoriasiform epidermal hyperplasia with lymphocytic spongiosis and perivascular inflammation. Paraneoplastic papuloerythroderma of Ofuji. Clinical photographs showing erythroderma with erythematous, scaly plaques on the (a) palms and (b) posterior trunk, and on the (c) anterior trunk with relative sparing of the abdominal skin folds (deck-chair sign). Paraneoplastic papuloerythroderma of Ofuji. Skin biopsy showing psoriasiform epidermal hyperplasia with focal lymphocytic spongiosis and superficial perivascular lymphocytic inflammation with scattered eosinophils (H&E, ×200). He was treated with modified Goeckerman therapy with partial improvement of his rash. Computed tomography of the chest revealed a 1.1-cm solid nodule in the left upper lobe, concerning a primary pulmonary neoplasm. The patient was diagnosed with pulmonary squamous cell carcinoma. Based on clinical, laboratory, and histopathologic findings, a diagnosis of paraneoplastic papuloerythroderma of Ofuji (PEO) was made. The patient underwent cancer-directed therapy for lung squamous cell carcinoma with targeted radiation (five fractions). Within four weeks of initiating radiation, he had marked improvement in generalized erythema and scaling, including near-resolution of palmoplantar hyperkeratosis and fissuring (Figure 3a–c). At follow-up after completion of oncologic therapy, his erythroderma remained controlled with no recurrence of diffuse skin involvement. Figure 3Response to cancer-directed therapy. Clinical photographs demonstrating marked improvement of generalized erythematous plaques and palmoplantar hyperkeratosis after five fractions of targeted radiation therapy for lung squamous cell carcinoma (a–c).The image A shows a man's hands with reduced palmoplantar hyperkeratosis, indicating improvement. The image B shows the man's back, displaying marked improvement in generalized erythematous plaques after targeted radiation therapy for lung squamous cell carcinoma. The image C shows the man's front, highlighting the near-resolution of skin scaling and fissuring. These images demonstrate the response to cancer-directed therapy, with significant skin condition improvement and controlled erythroderma.Clinical images showing improvement of plaques on palms, posterior trunk and anterior trunk following cancer-directed therapy. Response to cancer-directed therapy. Clinical photographs demonstrating marked improvement of generalized erythematous plaques and palmoplantar hyperkeratosis after five fractions of targeted radiation therapy for lung squamous cell carcinoma (a–c). Discussion Paraneoplastic papuloerythroderma of Ofuji (PEO) is a rare form of exfoliative erythroderma, and presents with intensely pruritic, generalized erythema and scaling that involves most or all of the body with sparing of the skin folds (deck-chair sign).1 It is frequently associated with malignancy (up to 54.5% of cases in one Japanese series), most commonly cutaneous T-cell lymphoma (CTCL), but has also been reported in association with lung cancer.1 Importantly, involvement of the palms and soles may occur, often presenting as palmoplantar keratoderma marked by thickened, scaly, and frequently fissured skin.2 Notably, the course often parallels the underlying malignancy; however, its onset may precede, coincide with, or follow the diagnosis of cancer.3 In our patient, diagnosis was particularly challenging because longstanding plaque psoriasis created a plausible alternative explanation for the abrupt progression to erythroderma, increasing the risk that the eruption would be attributed to psoriasis flare or treatment failure rather than prompting evaluation for a paraneoplastic process. The principal differential diagnoses in this case were erythrodermic psoriasis, drug-induced erythroderma, and CTCL. Although the patient had near-total body erythema and scale, the biopsy demonstrated marked spongiosis with a lymphocyte- and eosinophil-rich infiltrate, a pattern atypical for erythrodermic psoriasis, which more commonly shows psoriasiform epidermal hyperplasia with neutrophils and minimal to absent spongiosis or eosinophilia. Additionally, the presence of fold sparing (deck-chair sign) supported PEO over psoriasis, in which intertriginous involvement is common. Drug-related erythroderma (morbilliform eruption or evolving DRESS) is another important mimic and is often supported by a clear temporal association with a new medication, facial edema, fever, transaminitis, and prominent eosinophilia; however, our patient had no recent medication changes. CTCL (including Sézary syndrome) can also present with generalized erythroderma and lymphadenopathy, but it is characterized by a clonal proliferation of atypical T cells (often CD4 predominance with an elevated CD4:CD8 ratio), which was not seen in this case, as no malignant T-cell clone was identified on skin biopsy or peripheral blood studies. Due to its close resemblance to psoriasis or eczema, paraneoplastic PEO is challenging to diagnose, leading to initial treatments that are ineffective.4 The eruption typically persists until the underlying malignancy is treated; therefore, management centers on cancer-directed therapy. Sudden erythrodermic worsening in a patient with pre-existing inflammatory dermatoses, particularly when accompanied by fold sparing and clinicopathologic features not classic for psoriasis, should prompt reconsideration of the working diagnosis and evaluation for occult malignancy rather than being attributed to progression of the underlying disease alone. As a single case report, a causal relationship between the malignancy and the eruption cannot be definitively proven. The paraneoplastic association in our case is inferred from clinicopathologic correlation and improvement after cancer-directed therapy. Conclusion This case highlights the need to consider paraneoplastic PEO when a presumed inflammatory dermatosis becomes unusually severe and refractory to treatment. Paraneoplastic PEO can be an important early indicator of an occult malignancy.